#United States #Cambridge #Drug Discovery #Insilico Medicine #AI Benchmark

Announcing a New Era in Drug Discovery with Insilico Medicine's Benchmarking as a Service

In a significant advancement for the pharmaceuticals sector, Insilico Medicine has officially introduced the Drug Discovery and Development (DDD) Benchmark as a Service. This innovative benchmarking system will allow organizations engaged in drug discovery to evaluate frontier artificial intelligence models and foundation models against real-world scientific data. The need for such an evaluation tool arises from the rapid proliferation of both general-purpose and domain-specific artificial intelligence models in the drug discovery space, generating critical questions on their practical efficacy.

Many existing benchmarks for AI systems in this area suffer from substantial data contamination, providing misleadingly high scores that fail to reflect actual performance. In contrast, the DDD Benchmark is built on rigorously decontaminated data, offering an independent, standardized measurement of AI models' capabilities. Through this robust framework, organizations can determine whether their models are indeed innovating in drug discovery or merely performing well on theoretical assessments.

Understanding the DDD Benchmark

Insilico Medicine has developed the DDD Benchmark utilizing over 30 validated preclinical candidate (PCC) programs as well as 12 years of experience in model development. This initiative creates a large-scale